Animal trial backs use of RTI's BioCleanse process
This article was originally published in Clinica
Executive Summary
The BioCleanse tissue sterilisation process, developed by RTI Biologics, allows meniscal allografts to perform to the same standard as those that underwent standard aseptic processing, a trial has shown.
You may also be interested in...
Five minutes with… Noam Emanuel of PolyPid
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast's blood cancers stem cell therapy moves closer to market
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast stem cell therapy advances into Phase II for spinal degeneration
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: